Acadian Asset Management’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-797
Closed -$5K – 2148
2026
Q1
$5K Buy
+797
New +$8.39K ﹤0.01% 1988
2019
Q4
– Sell
-181
Closed -$3K – 2010
2019
Q3
$3K Sell
181
-124
-41% -$2.91K ﹤0.01% 1831
2019
Q2
$7K Buy
+305
New +$6.69K ﹤0.01% 1667
2015
Q4
– Sell
-32,008
Closed -$184K – 1476
2015
Q3
$184K Buy
+32,008
New +$198K ﹤0.01% 923
2014
Q3
– Sell
-42,545
Closed -$142K – 1091
2014
Q2
$142K Buy
42,545
+34,525
+430% +$115K ﹤0.01% 828
2014
Q1
$28K Buy
+8,020
New +$30K ﹤0.01% 903

Other funds holding NEO

Acadian Asset Management's NEO Position: Q2 2026 in Review

Acadian Asset Management sold out of NeoGenomics (NEO) in Q2 2026, closing a stake of 797 shares — an estimated $5K sold.

Acadian Asset Management first reported a position in NEO in Q1 2014 and held it in 6 quarters. The position peaked at $184K in Q3 2015. 266 funds tracked by Wall St. Rank hold NEO as of Q2 2026.

  • Acadian Asset Management reported no remaining NeoGenomics position as of Q2 2026 after selling out during the quarter.
  • Acadian Asset Management sold 797 NeoGenomics shares in Q2 2026, an estimated $5K.
  • Acadian Asset Management first reported a position in NeoGenomics in Q1 2014 and held it in 6 quarters.
  • Acadian Asset Management's NeoGenomics position peaked at $184K in Q3 2015.
  • 266 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.